X

Vous n'êtes pas connecté

Rubriques :

  - WN.COM - Health - 27/Aug 09:43

UAE Approves New Multiple Sclerosis Drug in World-First Ruling

In a landmark regulatory achievement that reflects the UAE’s leadership in accelerating access to innovative therapies, the Emirates Drug Establishment has announced the approval of “Tolebrutinib” as the world’s first oral treatment for non-relapsing secondary progressive multiple sclerosis (SPMS). This milestone underscores the nation’s commitment to providing advanced, science-based therapeutic solutions that enhance patients’ quality of life and align with global...

Articles similaires

Sorry! Image not available at this time

UAE Approves New Multiple Sclerosis Drug in World-First Ruling

wn.com - 27/Aug 09:43

In a landmark regulatory achievement that reflects the UAE’s leadership in accelerating access to innovative therapies, the Emirates Drug...

Sorry! Image not available at this time

What is Tolebrutinib? The world’s first oral treatment approved in UAE for progressive multiple sclerosis

times of india - 26/Aug 16:48

The UAE has approved Tolebrutinib, the world’s first oral treatment for non-relapsing secondary progressive multiple sclerosis (SPMS). Developed to...

Sorry! Image not available at this time

What is Tolebrutinib? The world’s first oral treatment approved in UAE for progressive multiple sclerosis

times of india - 26/Aug 16:48

The UAE has approved Tolebrutinib, the world’s first oral treatment for non-relapsing secondary progressive multiple sclerosis (SPMS). Developed to...

Sorry! Image not available at this time

Star Combo receives TGA approval on proprietary ingredient InuFructis

aumanufacturing.com.au - 24/Aug 23:19

Sponsored Leading Australian health and nutrition manufacturer Star Combo Pharma today announced that its proprietary natural sweetener InuFructis has...

Sorry! Image not available at this time

Explore the Weight Loss & Diabetes Drug Battle: Ozempic vs. Mounjaro vs. Wegovy

wn.com - 21/Aug 12:14

"Ozempic vs. Mounjaro vs. Wegovy" Together, Wegovy and Zepbound generated USD 10.8B in recent sales, projected to exceed USD 22.5B by 2034. The weight...

Sorry! Image not available at this time

Explore the Weight Loss & Diabetes Drug Battle: Ozempic vs. Mounjaro vs. Wegovy

wn.com - 21/Aug 12:14

"Ozempic vs. Mounjaro vs. Wegovy" Together, Wegovy and Zepbound generated USD 10.8B in recent sales, projected to exceed USD 22.5B by 2034. The weight...

Sorry! Image not available at this time

A Celebration of Watch Culture: Siam Paragon Unveils Southeast Asia’s First-Ever World-Class Watch Showcase

technologymirror.com.ng - 29/Aug 06:05

Positioning Bangkok as a global luxury watch hub, Siam Paragon presents “Bangkok Watch Week 2025” from September 23–28, a phenomenal horology...

Sorry! Image not available at this time

A Celebration of Watch Culture: Siam Paragon Unveils Southeast Asia’s First-Ever World-Class Watch Showcase

technologymirror.com.ng - 29/Aug 06:05

Positioning Bangkok as a global luxury watch hub, Siam Paragon presents “Bangkok Watch Week 2025” from September 23–28, a phenomenal horology...

Sorry! Image not available at this time

CRISPR Pipeline Outlook 2025: Clinical Trial Studies, EMA, PDMA, FDA Approvals, MOA, ROA, NDA, IND, ...

wn.com - 00:19

DelveInsight’s, “CRISPR Therapies Pipeline Insight, 2025,” report provides comprehensive insights about 25+ companies and 30+...

Sorry! Image not available at this time

CRISPR Pipeline Outlook 2025: Clinical Trial Studies, EMA, PDMA, FDA Approvals, MOA, ROA, NDA, IND, ...

wn.com - 00:19

DelveInsight’s, “CRISPR Therapies Pipeline Insight, 2025,” report provides comprehensive insights about 25+ companies and 30+...

Les derniers communiqués